Ivabradine use in refractory unstable angina: A case report

C. Ripa, G. Germano, A. Caparra, C. A. Capparuccia, Roberto Antonicelli

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In this report, we describe the clinical results of ivabradine use in a patient with a serious form of unstable angina. For this patient, it was proposed that no other therapeutic, pharmacologic or surgical, option was available. The patient is a 75-year-old woman who presented with repeated episodes of retrosternal chest pain. She notably had a history of type II diabetes mellitus treated by insulin for several years and complicated by diabetic macro-angiopathy. ECG tracings recorded during these episodes showed abnormalities of the lateral repolarization phase of ischaemic nature. There was no measured increase in cardiac enzymes. She was transferred to our CCU with a diagnosis of unstable angina. In our CCU, the patient was treated with nitrates, metoprolol, aspirin, clopidogrel and atorvastatin at maximal sustainable doses. Following persistent clinical-instrumental instability, she was subjected to coronary angiography. This study revealed severe multi-vessel coronary artery disease not amenable to surgery or angioplasty revascularization. In addition to the therapy already provided, a beta-blocker (metoprolol 50 mg x 2/die) and diltiazem (30 mg x 2/die) were added despite their potentially dangerous and adverse chronotropic effects. Despite this treatment, the patient's heart rate remained high (between 80 and 100 beats/min). This heart rate appeared to be the main driving cause of her anginal symptoms. At this point, the use of ivabradine seemed the only option, even though use would be 'off-label' compared to current indications for the drug's use. We started with a low dose of 2.5 mg/b.i.d. and titrated up to 5 mg b.i.d. As we titrated, we witnessed a gradual reduction in heart rate. A consequent stabilization of her clinical pattern progressed into an almost unexpected asymptomatic state. After about a week of clinical observation, the patient recovered. After three months, she remains asymptomatic.

Original languageEnglish
Pages (from-to)849-852
Number of pages4
JournalInternational Journal of Immunopathology and Pharmacology
Volume22
Issue number3
Publication statusPublished - Jul 2009

Fingerprint

ivabradine
Unstable Angina
Metoprolol
Heart Rate
clopidogrel
Asymptomatic Diseases
Diabetic Angiopathies
Diltiazem
Coronary Angiography
Chest Pain
Angioplasty
Nitrates
Type 2 Diabetes Mellitus
Aspirin
Coronary Artery Disease
Electrocardiography
Therapeutics
Observation
Insulin

Keywords

  • Ivabradine
  • Unstable angina

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Cite this

Ivabradine use in refractory unstable angina : A case report. / Ripa, C.; Germano, G.; Caparra, A.; Capparuccia, C. A.; Antonicelli, Roberto.

In: International Journal of Immunopathology and Pharmacology, Vol. 22, No. 3, 07.2009, p. 849-852.

Research output: Contribution to journalArticle

Ripa, C, Germano, G, Caparra, A, Capparuccia, CA & Antonicelli, R 2009, 'Ivabradine use in refractory unstable angina: A case report', International Journal of Immunopathology and Pharmacology, vol. 22, no. 3, pp. 849-852.
Ripa, C. ; Germano, G. ; Caparra, A. ; Capparuccia, C. A. ; Antonicelli, Roberto. / Ivabradine use in refractory unstable angina : A case report. In: International Journal of Immunopathology and Pharmacology. 2009 ; Vol. 22, No. 3. pp. 849-852.
@article{30a258509d3643e1acca854f41c8772c,
title = "Ivabradine use in refractory unstable angina: A case report",
abstract = "In this report, we describe the clinical results of ivabradine use in a patient with a serious form of unstable angina. For this patient, it was proposed that no other therapeutic, pharmacologic or surgical, option was available. The patient is a 75-year-old woman who presented with repeated episodes of retrosternal chest pain. She notably had a history of type II diabetes mellitus treated by insulin for several years and complicated by diabetic macro-angiopathy. ECG tracings recorded during these episodes showed abnormalities of the lateral repolarization phase of ischaemic nature. There was no measured increase in cardiac enzymes. She was transferred to our CCU with a diagnosis of unstable angina. In our CCU, the patient was treated with nitrates, metoprolol, aspirin, clopidogrel and atorvastatin at maximal sustainable doses. Following persistent clinical-instrumental instability, she was subjected to coronary angiography. This study revealed severe multi-vessel coronary artery disease not amenable to surgery or angioplasty revascularization. In addition to the therapy already provided, a beta-blocker (metoprolol 50 mg x 2/die) and diltiazem (30 mg x 2/die) were added despite their potentially dangerous and adverse chronotropic effects. Despite this treatment, the patient's heart rate remained high (between 80 and 100 beats/min). This heart rate appeared to be the main driving cause of her anginal symptoms. At this point, the use of ivabradine seemed the only option, even though use would be 'off-label' compared to current indications for the drug's use. We started with a low dose of 2.5 mg/b.i.d. and titrated up to 5 mg b.i.d. As we titrated, we witnessed a gradual reduction in heart rate. A consequent stabilization of her clinical pattern progressed into an almost unexpected asymptomatic state. After about a week of clinical observation, the patient recovered. After three months, she remains asymptomatic.",
keywords = "Ivabradine, Unstable angina",
author = "C. Ripa and G. Germano and A. Caparra and Capparuccia, {C. A.} and Roberto Antonicelli",
year = "2009",
month = "7",
language = "English",
volume = "22",
pages = "849--852",
journal = "International Journal of Immunopathology and Pharmacology",
issn = "0394-6320",
publisher = "Biomedical Research Press s.a.s.",
number = "3",

}

TY - JOUR

T1 - Ivabradine use in refractory unstable angina

T2 - A case report

AU - Ripa, C.

AU - Germano, G.

AU - Caparra, A.

AU - Capparuccia, C. A.

AU - Antonicelli, Roberto

PY - 2009/7

Y1 - 2009/7

N2 - In this report, we describe the clinical results of ivabradine use in a patient with a serious form of unstable angina. For this patient, it was proposed that no other therapeutic, pharmacologic or surgical, option was available. The patient is a 75-year-old woman who presented with repeated episodes of retrosternal chest pain. She notably had a history of type II diabetes mellitus treated by insulin for several years and complicated by diabetic macro-angiopathy. ECG tracings recorded during these episodes showed abnormalities of the lateral repolarization phase of ischaemic nature. There was no measured increase in cardiac enzymes. She was transferred to our CCU with a diagnosis of unstable angina. In our CCU, the patient was treated with nitrates, metoprolol, aspirin, clopidogrel and atorvastatin at maximal sustainable doses. Following persistent clinical-instrumental instability, she was subjected to coronary angiography. This study revealed severe multi-vessel coronary artery disease not amenable to surgery or angioplasty revascularization. In addition to the therapy already provided, a beta-blocker (metoprolol 50 mg x 2/die) and diltiazem (30 mg x 2/die) were added despite their potentially dangerous and adverse chronotropic effects. Despite this treatment, the patient's heart rate remained high (between 80 and 100 beats/min). This heart rate appeared to be the main driving cause of her anginal symptoms. At this point, the use of ivabradine seemed the only option, even though use would be 'off-label' compared to current indications for the drug's use. We started with a low dose of 2.5 mg/b.i.d. and titrated up to 5 mg b.i.d. As we titrated, we witnessed a gradual reduction in heart rate. A consequent stabilization of her clinical pattern progressed into an almost unexpected asymptomatic state. After about a week of clinical observation, the patient recovered. After three months, she remains asymptomatic.

AB - In this report, we describe the clinical results of ivabradine use in a patient with a serious form of unstable angina. For this patient, it was proposed that no other therapeutic, pharmacologic or surgical, option was available. The patient is a 75-year-old woman who presented with repeated episodes of retrosternal chest pain. She notably had a history of type II diabetes mellitus treated by insulin for several years and complicated by diabetic macro-angiopathy. ECG tracings recorded during these episodes showed abnormalities of the lateral repolarization phase of ischaemic nature. There was no measured increase in cardiac enzymes. She was transferred to our CCU with a diagnosis of unstable angina. In our CCU, the patient was treated with nitrates, metoprolol, aspirin, clopidogrel and atorvastatin at maximal sustainable doses. Following persistent clinical-instrumental instability, she was subjected to coronary angiography. This study revealed severe multi-vessel coronary artery disease not amenable to surgery or angioplasty revascularization. In addition to the therapy already provided, a beta-blocker (metoprolol 50 mg x 2/die) and diltiazem (30 mg x 2/die) were added despite their potentially dangerous and adverse chronotropic effects. Despite this treatment, the patient's heart rate remained high (between 80 and 100 beats/min). This heart rate appeared to be the main driving cause of her anginal symptoms. At this point, the use of ivabradine seemed the only option, even though use would be 'off-label' compared to current indications for the drug's use. We started with a low dose of 2.5 mg/b.i.d. and titrated up to 5 mg b.i.d. As we titrated, we witnessed a gradual reduction in heart rate. A consequent stabilization of her clinical pattern progressed into an almost unexpected asymptomatic state. After about a week of clinical observation, the patient recovered. After three months, she remains asymptomatic.

KW - Ivabradine

KW - Unstable angina

UR - http://www.scopus.com/inward/record.url?scp=70350564087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350564087&partnerID=8YFLogxK

M3 - Article

C2 - 19822102

AN - SCOPUS:70350564087

VL - 22

SP - 849

EP - 852

JO - International Journal of Immunopathology and Pharmacology

JF - International Journal of Immunopathology and Pharmacology

SN - 0394-6320

IS - 3

ER -